跳至主要内容
临床试验/ACTRN12621000212853
ACTRN12621000212853已完成未知

Effect of Yeast protein compared to whey protein and a placebo on muscle mass and performance in an Adult Population – A double blind, randomised controlled trial.

RDC Global Pty Ltd.0 个研究点目标入组 127 人开始时间: 2021年3月3日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
127

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
40 Years 至 o limit(—)
性别
Male

入选标准

  • Male aged over 40 years old
  • BMI 20.0-34.9
  • Able to provide informed consent
  • Undertaking low impact cardiovascular exercise including but not limited to cycling, swimming and walking not more than 5 x weekly
  • Agree not to take other supplements (including protein or testosterone containing supplements) or medications (e.g. steroids) aimed at muscle mass growth for the duration of the trial.

排除标准

  • Currently undertaking resistance training exercise more than once a week
  • Unstable or serious illness/impairment (e.g. kidney, liver, GIT, heart conditions, diabetes, thyroid gland function, Malignancy, lung conditions, chronic asthma, cognitive damage, mood disorders or neurological disorders such as MS)*
  • Acute sickness experienced in the past 2 months
  • Active smokers and/or nicotine or drug abuse
  • Chronic alcohol use (>14 alcoholic drinks week)
  • Allergic to any of the ingredients in active or placebo formula (e.g. milk, whey or yeast allergy)
  • Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion
  • Participants who have participated in any other exercise based clinical study during the past 3 month
  • People who have or have had treatment for cancer, HIV or use of anabolic steroids in the past year.
  • History of orthopedic injuries or surgery in the past 6 months
  • *An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.

研究者

相似试验